Benefits and risks of antiretroviral therapy for perinatal HIV prevention

New England Journal of Medicine

Volumn 375, Issue 18, 2016, Pages 1726-1737

  Fowler, M G ^a   Qin, M ^e   Fiscus, S A ^f   Currier, J S ^h   Flynn, P M ⁱ   Chipato, T ^j   McIntyre, J ^k,n   Gnanashanmugam, D ^c   Siberry, G K ^d   Coletti, A S ^g   Taha, T E ^b   Klingman, K L ^c   Martinson, F E ^r   Owor, M ^s   Violari, A ^l   Moodley, D ^p   Theron, G B ^o   Bhosale, R ^t   Bobat, R ^q   Chi, B H ^u   Strehlau, R ^m   Mlay, P ^v   Loftis, A J ^f   Browning, R ^c   Fenton, T ^e   Purdue, L ^c   Basar, M ^w   Shapiro, D E ^e   Mofenson, L M ^x   more..

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^e CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^g FAMILY HEALTH INTERNATIONAL   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^j UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^k ANOVA HEALTH INSTITUTE   (South Africa)

^l UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^m Faculty of Health Sciences Empilweni Services and Research Unit Department of Paediatrics and Child Health   (South Africa)

ⁿ UNIVERSITY OF CAPE TOWN   (South Africa)

^o STELLENBOSCH UNIVERSITY   (South Africa)

^p UNIVERSITY OF KWAZULU NATAL   (South Africa)

^q UNIVERSITY OF KWAZULU NATAL   (South Africa)

^r UNIVERSITY OF NORTH CAROLINA PROJECT   (Malawi)

^s JOHNS HOPKINS UNIVERSITY   (United States)

^t B J MEDICAL COLLEGE   (India)

^u CENTRE FOR INFECTIOUS DISEASE RESEARCH IN ZAMBIA   (Zambia)

^v KILIMANJARO CHRISTIAN MEDICAL CENTRE   (Tanzania)

^w FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^x ELIZABETH GLASER PEDIATRIC AIDS FOUNDATION   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; CREATININE; EMTRICITABINE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; TENOFOVIR; ZIDOVUDINE;

AFRICAN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLACK PERSON; CD4 LYMPHOCYTE COUNT; CREATININE BLOOD LEVEL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GESTATIONAL AGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; NEWBORN; PATIENT SAFETY; PERINATAL PERIOD; PREGNANCY OUTCOME; PREGNANT WOMAN; PREMATURE LABOR; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; VERTICAL TRANSMISSION; ADULT; AFRICAN AMERICAN; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; ETHNOLOGY; HIV INFECTIONS; INFANT; INFANT MORTALITY; MULTICENTER STUDY; PERINATAL CARE; PREGNANCY; PREMATURITY; PREVENTION AND CONTROL; RANDOMIZED CONTROLLED TRIAL; TRANSMISSION; YOUNG ADULT;

ADULT; AFRICAN AMERICANS; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; FEMALE; GESTATIONAL AGE; HIV INFECTIONS; HUMANS; INFANT; INFANT MORTALITY; INFANT, LOW BIRTH WEIGHT; INFANT, NEWBORN; INFANT, PREMATURE; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; NEVIRAPINE; PERINATAL CARE; PREGNANCY; PREGNANCY OUTCOME; TENOFOVIR; YOUNG ADULT; ZIDOVUDINE;

EID: 84994106628     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1511691     Document Type: Article

References (27)

1. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994; 331: 1173-80
2. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Rockville, MD: AIDSinfo, 2016 (http://aidsinfo .nih .gov/ contentfiles/ lvguidelines/ Perinatal GL .pdf)
3. Mofenson LM. Antiretroviral therapy and adverse pregnancy outcome: The elephant in the room?. J Infect Dis 2016; 213: 1051-4
4. Chen JY, Ribaudo HJ, Souda S, et al. Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana. J Infect Dis 2012; 206: 1695-705
5. Li N, Sando MM, Spiegelman D, et al. Antiretroviral therapy in relation to birth outcomes among HIV-infected women: A cohort study. J Infect Dis 2016; 213: 1057-64
6. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: Recommendations for a public health approach. Geneva: World Health Organization, 2010 (http://whqlibdoc .who .int/ publications/ 2010/ 9789241599818-eng .pdf?ua=1)
7. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS table for grading the severity of adult and pediatric adverse events, version 1.0. August 2009 (http://rsc.tech-res.com/ docs/default-source/safety/table-for- grading-severity-of-adult-pediatric- adverse-events.pdf)
8. Marchant T, Willey B, Katz J, et al. Neonatal mortality risk associated with preterm birth in East Africa, adjusted by weight for gestational age: Individual participant level meta-analysis. PLoS Med 2012; 9(8): E1001292
9. Liu L, Johnson HL, Cousens S, et al. Global, regional, and national causes of child mortality: An updated systematic analysis for 2010 with time trends since 2000. Lancet 2012; 379: 2151-61
10. Katz J, Lee AC, Kozuki N, et al. Mortality risk in preterm and small-for-gestational-age infants in low-income and middle-income countries: A pooled country analysis. Lancet 2013; 382: 417-25
11. Taha TE, Dadabhai SS, Sun J, Rahman MH, Kumwenda J, Kumwenda N. Child mortality levels and trends by HIV status in Blantyre, Malawi: 1989-2009. J Acquir Immune Defic Syndr 2012; 61: 226-34
12. Zash R, Souda S, Chen JY, et al. Reassuring birth outcomes with tenofovir/ emtricitabine/efavirenz used for prevention of mother-to-child transmission of HIV in Botswana. J Acquir Immune Defic Syndr 2016; 71: 428-36
13. Kiser JJ, Carten ML, Aquilante CL, et al. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther 2008; 83: 265-72
14. Kearney BP, Mathias A, Mittan A, Sayre J, Ebrahimi R, Cheng AK. Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ ritonavir. J Acquir Immune Defic Syndr 2006; 43: 278-83
15. Pruvost A, Negredo E, Théodoro F, et al. Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): Investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir. Antimicrob Agents Chemother 2009; 53: 1937-43
16. Stek AM, Mirochnick M, Capparelli E, et al. Reduced lopinavir exposure during pregnancy. AIDS 2006; 20: 1931-9
17. Mirochnick M, Best BM, Stek AM, et al. Lopinavir exposure with an increased dose during pregnancy. J Acquir Immune Defic Syndr 2008; 49: 485-91
18. Watts DH, Williams PL, Kacanek D, et al. Combination antiretroviral use and preterm birth. J Infect Dis 2013; 207: 612-21
19. Kourtis AP, Fowler MG. Antiretroviral use during pregnancy and risk of preterm delivery: More questions than answers. J Infect Dis 2011; 204: 493-4
20. Sibiude J, Warszawski J, Tubiana R, et al. Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: Role of the ritonavir boost?. Clin Infect Dis 2012; 54: 1348-60
21. Powis KM, Kitch D, Ogwu A, et al. Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy. J Infect Dis 2011; 204: 506-14
22. Papp E, Mohammadi H, Loutfy MR, et al. HIV protease inhibitor use during pregnancy is associated with decreased progesterone levels, suggesting a potential mechanism contributing to fetal growth restriction. J Infect Dis 2015; 211: 10-8
23. Papp E, Balogun K, Banko N, et al. Low prolactin and high 20-α-hydroxysteroid dehydrogenase levels contribute to lower progesterone levels in HIV-infected pregnant women exposed to protease inhibitor-based combination antiretroviral therapy. J Infect Dis 2016; 213: 1532-40
24. Powis KM, Shapiro RL. Protease inhibitors and adverse birth outcomes: Is progesterone the missing piece to the puzzle?. J Infect Dis 2015; 211: 4-7
25. Caritis SN, Venkataramanan R, Thom E, et al. Relationship between 17-alpha hydroxyprogesterone caproate concentration and spontaneous preterm birth. Am J Obstet Gynecol 2014; 210(2): 128.e1-6
26. The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 2015; 373: 795-807
27. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: World Health Organization, September 2015 (http://www .who .int/ hiv/ pub/ guidelines/ earlyrelease-arv/ en/).